Assystem

Assystem has fallen dramatically from its February high of around €48.30 to approximately €34, leaving investors with an intriguing question: is the market seeing a serious problem that others are missing, or is this a temporary valuation opportunity? The recent weakness has been driven by several concerns, including the postponement of first-half 2026 results, weaker international operations, currency headwinds, and uncertainty surrounding Expleo. The underlying business picture is more encouraging. First-half revenue reached €328.5 million, representing 0.6% growth, while nuclear revenue increased 8% organically and reached 81% of total revenue. France and the United Kingdom continued to perform particularly well. Assystem is targeting 2% to 4% organic revenue growth and an EBIT-A margin of approximately 7% for 2026. The major risk is Expleo, which faces financing pressure and needs to address €70 million of debt. The delayed financial results have increased uncertainty and could keep investors cautious. For value investors, the attraction is the combination of a substantially lower share price and strong nuclear-sector exposure. However, recovery depends on reassuring financial results, better international performance, and progress at Expleo. Dividend growth and capital allocation also deserve attention. This review is for informational and educational purposes only, not financial advice.